Acid ceramidase and its inhibitors: a de novo drug target and a new class of drugs for killing glioblastoma cancer stem cells with high efficiency

Glioblastoma remains the most common, malignant primary cancer of the central nervous system with a low life expectancy and an overall survival of less than 1.5 years. The treatment options are limited and there is no cure. Moreover, almost all patients develop recurrent tumors, which typically are...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncotarget
Autors principals: Doan, Ninh B., Alhajala, Hisham, Al-Gizawiy, Mona M., Mueller, Wade M., Rand, Scott D., Connelly, Jennifer M., Cochran, Elizabeth J., Chitambar, Christopher R., Clark, Paul, Kuo, John, Schmainda, Kathleen M., Mirza, Shama P.
Format: Artigo
Idioma:Inglês
Publicat: Impact Journals LLC 2017
Matèries:
Research Paper
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5762539/
https://ncbi.nlm.nih.gov/pubmed/29348854
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22637
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars